Compassionate Use Case Study Demonstrating the Potential of Investigational Direct Lytic Agent Exebacase to Treat MRSA Bacteremia in Pediatric Populations Published in Clinical Infectious Diseases

Ads

You May Also Like

OncBioMune Selects Theradex as CRO for Two Phase 2 Trials of ProscaVax for Prostate Cancer

BATON ROUGE, La., March 08, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" ...

New Lactation Rooms Added to the ABOG Educational Foundation Test Center

Certifying Exam Candidates and Examiners Provide Positive Feedback About the AccommodationsDallas, Texas, Feb. 05, ...

G1 Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 14, 2018

RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: ...